- Open Access
The hyper-activation of transcriptional enhancers in breast cancer
Clinical Epigenetics volume 11, Article number: 48 (2019)
Activation of transcription enhancers, especially super-enhancers, is one of the critical epigenetic features of tumorigenesis. However, very few studies have systematically identified the enhancers specific in cancer tissues.
Here, we studied the change of histone modifications in MMTV-PyVT breast cancer model, combining mass spectrometry-based proteomics and ChIP-seq-based epigenomics approaches. Some of the proteomic results were confirmed with western blotting and IHC staining. An inhibitor of H3K27ac was applied to study its effect on cancer development.
H3K27ac and H4K8ac are elevated in cancer, which was confirmed in patient tissue chips. ChIP-seq revealed that H4K8ac is co-localized with H3K27ac on chromatin, especially on distal enhancers. Epigenomic studies further identified a subgroup of super-enhancers marked by H3K4me3 peaks in the intergenic regions. The H3K4me3-enriched regions enhancers are associated with higher level of H3K27ac and H4K8ac compared with the average level of conventional super-enhancers and are associated with higher transcription level of their adjacent genes. We identified 148 H3K4me3-enriched super-enhancers with higher gene expression in tumor, which may be critical for breast cancer. One inhibitor for p300 and H3K27ac, C646, repressed tumor formation probably through inhibiting Vegfa and other genes.
Taken together, our work identifies novel regulators and provides important resource to the genome-wide enhancer studies in breast cancer and raises the possibility of cancer treatment through modulating enhancer activity.
The recent advances in epigenetics and genomics have revealed the critical roles of epigenetic factors in cancer. The dynamic regulation of histone acetylation and methylation becomes critical for chromatin stability, tumorigenesis, and metastasis [1,2,3]. Inhibitors for histone deacetylases (HDACs) have been approved to be used in clinical treatment, such as SAHA and VPA . Recently, inhibitors for histone acetylation readers have become another new family of promising drugs in cancer treatment . Besides these, quite a few of histone methyltransferases and demethylases have been characterized as key molecules in cancer. SET domain containing 2 (SETD2), a major H3K36me3 methyltransferase in mammalian cells, is frequently mutated in clear cell renal carcinoma, leukemia, glioma, and other cancers, and H3K36me3 catalyzed by SETD2 is involved in mRNA alternative splicing, genome stability, and DNA repair process [6,7,8]. Myeloid/lymphoid or mixed-lineage leukemia 1–4 (MLL1–4), the methyltransferases for H3K4, are often mutated in multiple types of cancers [1, 9]. On the other hand, histone demethylases are often related with tumorigenesis. Clinical studies found that the demethylases of H3K9me2 and me3, such as lysine (K)-specific demethylase 3A (KDM3A, also known as JMJD1A or JHDM2A) and lysine (K)-specific demethylase 4A/B/C (KDM4A/B/C), are highly expressed in cancer tissues and regulate tumorigenesis [10,11,12]. Thus, to understand the spatiotemporal regulation of epigenetic dynamics is critical for current cancer research.
Along with the development of next-generation sequencing (NGS), epigenomics has gained the focus of cancer research field. Especially, the reprogramming of distal enhancers has emerged as one of the important features for tumor [1, 13]. Classically, the enhancers were thought to locate within several kb from transcription start sites (TSS). However, recent studies revealed that in fact most of the enhancers are much farther away from TSS, often over several hundreds of kb away, so-called distal enhancers [13,14,15]. Enhancers are usually marked with H3K4me1, which is catalyzed by histone methyltransferase MLL3/4 [16, 17]. The active enhancers are further labeled with H3K27ac and bound by mediator complex, which facilitates enhancer-promoter crosstalk [13, 18, 19]. Nowadays, H3K27ac is often used as a mark to identify active enhancers and p300 is the corresponding histone acetyltransferase [20, 21]. A portion of enhancers gather together, form wide regions on chromatin with high level of H3K27ac, and extend about 10 kb and sometimes even longer, which are called super-enhancers [5, 22,23,24]. Super-enhancers are believed to contain high transcription activity, control the expression of master genes in the cell, and can be used for cell identification. In the tumor cells, super-enhancers are the potential critical regulatory elements on chromatin, often associated with activated oncogenes . Therefore, the genomic landscapes of super-enhancers in different cancers have to be illustrated, and the molecular mechanisms regulating the activity of super-enhancers need to be elucidated.
In the current study, we utilized a mass spectrometry-based proteomic approach and studied the difference of histone modifications between tumor and normal tissues of the MMTV-PyVT breast cancer mouse model. We found many histone modifications, including H3K27ac and H4K8ac, are changed in breast cancer tissues. We further studied their genome distributions through the ChIP-seq-based epigenomic approach and identified a lot of cancer-specific super-enhancers. Further analysis established a subgroup of super-enhancers with H3K4me3 as potential important regulatory elements for cancer. Unfortunately, we did not find a chemical inhibitor for H3K4me3, but we successfully repressed tumor growth through inhibiting H3K27ac with a specific small molecule.
The proteomic studies of the normal and breast cancer tissues
A mass spectrometry-based proteomic approach was utilized in this study to characterize histone post-translational modifications (PTMs) in the normal and breast cancer tissues of the MMTV-PyVT mice model. The experimental workflow is illustrated in Fig. 1a. Three biological replicates were included for both normal and breast cancer tissues. Histone proteins were extracted from breast tissues by acid extraction. Histones were chemically propionylated at lysine residues and peptide N-terminus using propionic anhydride and then digested with trypsin. The resulting Arg-C like histone peptides were composed of 7 to 20 amino acids and subjected to LC-MS/MS analysis operated in data-independent acquisition (DIA) mode. The dynamic histone PTMs were identified and quantified by using EpiProfile [25, 26]. Two examples for histone H3 peptide KSAPATGGVKKPHR (aa 27-40) and H4 peptide GKGGKGLGKGGAKR (aa 4-17) were displayed in Additional file 1: Figure S1A and B. Both peptides were detected in multiple PTMs forms, 15 forms for KSAPATGGVKKPHR and 16 for GKGGKGLGKGGAKR, respectively. The retention times and peak areas of these two histone peptides in multiple PTMs forms were extracted under the curve in mass spectra. The histone peptide with multiple PTMs was quantified in relative abundance, the percentage of the area of this histone peptide with particular PTM in summed total area of the histone peptide in all forms [27,28,29]. Since proteins must be digested into small fragments for mass spec analysis, the long distance multiple PTMs cannot be identified with the approach.
A total of 184 histone peptides including 139 peptides carrying one or more modifications were analyzed (Additional file 2: Table S1). A total of 96 single histone marks were characterized, including 36 marks located in histone H3, 8 in H4, 39 in H2A/B, and 13 in H1 (Fig. 1b and Additional file 2: Table S1). For histone H3 and H4 which are of most interests due to the high occupancy of multiple PTMs on the N-terminal tails, 64 H3 peptides and 23 H4 peptides were quantified, respectively. The relative abundances of histone H3 and H4 peptides in all modified forms were listed in Additional file 2: Table S2. The H3 and H4 peptides generated in this study were found to carry single and co-existing PTMs (Additional file 1: Figure S2A). The abundances of single marks on histone H3 and H4 were calculated by summing the percentages of this modification in all peptide forms and then compared between tumor and normal as listed in Additional file 1: Figure S2B and Additional file 2: Table S3. A heat map representing all the 44 single marks on histone H3 and H4 across all biological replicates under both conditions was illustrated in Fig. 1c. Good reproducibility between biological replicates was obtained and an obvious difference between normal and tumor breast tissues was clearly displayed. The volcano plot made by plotting the fold changes and statistical p values further confirmed the significant changes of individual histone single marks in tumor (Fig. 1d). Detailed information for the changes in relative abundances of single marks on H3 and H4 was illustrated in the histogram in Additional file 1: Figure S2B. The abundances of most acetylations appeared to increase in tumor tissues, including H3K4ac, H3K18ac, H4K8ac, H3K27ac, and H4K12ac. Meanwhile, methylations showed diverse regulation. H3K4me3 and H3K36me1/me2 showed a significant increase in tumor, whereas H3K23me1, H3K36me3, and H4K20me3 decreased in tumor.
The global level of histone modifications verified by western blot
To confirm the above results, we performed western blotting of each identified modification in cancer and normal breast tissues. We did not get good antibodies for some modifications, such as H3K4ac, and then we have to just verify some of the altered single modifications (Fig. 1e). The increase of H4K8ac in tumor was confirmed with two different antibodies, and H4K12ac and H3K18ac also exhibited an obvious increase. H3K23ac increased in tumor tissues, while H3K23me1 decreased. H3K27ac only increased slightly, but we kept observing it in multiple repeats. H3K9ac did not change obviously while H3K9me2 seemed to increase in tumor. H3K36me3 also decreased in tumor. Since the peptides for H3K4 modifications are too short, their mass spec results usually not very reliable. Also, considering the difference between the nature of two techniques, some discrepancies were expected. The trends of H4K8ac, H4K12ac, H3K18ac, H3K23me1, H3K23ac, H3K27ac, and H3K36me3 were similar to the proteomic results, confirming these modifications probably did change during tumorigenesis.
Epigenomic analysis showed the high correlation between H3K27ac and H4K8ac
To further investigate the dynamic chromatin distribution of the above modifications, we performed ChIP-seq analysis. We did not find ChIP-grade antibodies for H3K18ac, H4K12ac, H3K23me1, and H3K23ac, so we only studied the genome localization of H3K27ac, H4K8ac, H3K4me3, and H3K27me3. Here, we used H3K4me3 and H3K27me3 as controls for active and negative gene transcription. The tumors from three different mice were analyzed. For the group of normal tissues, since the tissue amount from one mouse were not enough, we collected and mixed the tissues from three mice for one analysis, and totally three biological replicates were studied.
Our analysis indicated the total peak number of H3K27ac increased in tumor tissues, but that of the other three did not change obviously (Fig. 2a). The signal intensity of all four modifications all increased in tumor, though H4K8ac only increased a small amount (Fig. 2b). Their trends seemed not fully matching the proteomic results and we guessed it was probably due to the use of different normalization standards, input DNA for ChIP-Seq, and total histones for proteomics. Nevertheless, both H3K27ac and H4K8ac increased in tumor tissues, which is similar to the proteomic results.
We then studied the association of chromatin distribution among four modifications in the normal and tumor groups. H3K27me3 was very different from others as expected, while H3K4me3 is quite similar to histone acetylation, since they are all marks for active transcription (Fig. 2c). Interestingly, H3K27ac and H4K8ac showed very high correlation, suggesting their sites were highly overlapped (Fig. 2c). The chromatin distributions of H3K27ac and H4K8ac peaks were similar, both enriched in intergenic regions and introns, and their peak numbers both increased in the intergenic regions in tumor tissues (Fig. 2d, e), suggesting a potential relationship between the change of H3K27ac and H4K8ac in the intergenic regions.
H3K27ac and H4K8ac are both enriched on distal enhancers
We then analyzed the H4K8ac signal on H3K27ac regions and found that H4K8ac peaked at the center of the global H3K27ac regions, as well as the distal enhancers (Fig. 2f). The further study indicated that H3K27ac and H4K8ac were highly correlated at the genome-wide scale in both normal and tumor tissues (Additional file 1: Figure S3A and B). When looking at the enhancer regions, the correlation of the two modifications was even higher (Fig. 2g). To further support our finding, we downloaded the ChIP-seq data in IMR-90 cells from ENCODE (https://www.encodeproject.org/, or GEO Acc. GSE16256), and the analysis also indicated that H3K27ac and H4K8ac were correlated genome-widely and higher on enhancers (Additional file 1: Figure S3C). All these indicated that H4K8ac is highly correlated with H3K27ac, especially on enhancers, which suggests H4K8ac can perhaps be used as another marker for enhancers.
Hyper-activation of super-enhancers in the breast cancer tissues
The above data indicated that H3K27ac and H4K8ac are higher in tumor, which suggests the enhancer activity in tumor was potentially higher. The early study found that super-enhancers in cancer cells are enriched at oncogenes and others important in tumor pathogenesis. . So, we analyzed the potential roles of super-enhancers in our model. We first identified the super and typical enhancers in the tumor and normal tissues according to the previous description  (Fig. 3a and Additional file 1: Figure S4A). On the super and typical enhancers identified in tumor, H3K27ac level was much higher in tumor than that in normal tissues (Fig. 3b). We hypothesized that the adjacent genes represent their target genes. The expression of genes adjacent to tumor super-enhancers increased more than those adjacent to typical enhancers and others (Fig. 3c), and the genes adjacent to tumor super-enhancers were enriched in cancer-related pathways (Fig. 3d). Totally, 624 genes were identified adjacent to tumor super-enhancers, among which 266 genes expressed higher in tumor tissues (Fig. 3e). Two representative genes, Xbp1 and Pak4, were shown in Fig. 3f. As a comparison, the genes adjacent to super-enhancers of normal tissues did not express more in tumor (Additional file 1: Figure S4B). The adjacent genes of tumor super-enhancers, compared with those unique in normal tissues, were more related with cancer (Fig. 3g–i). These data are consistent with the previous report that the activation of super-enhancers represents tumor characteristics . Our analysis confirmed the previous hypothesis about the role of super-enhancers in cancer and identified a group of super-enhancers important for cancer growth and development in the current model (Additional file 2: Table S4).
The elevation of H3K27ac and H4K8ac in the patient breast cancer tissues
Then, we investigated whether our finding about H3K27ac and H4K8ac is true in human patient breast tumor tissues. We purchased two sets of commercialized slides, which were accompanied with tumor molecular information. IHC staining was performed with H3K27ac and H4K8ac antibodies, respectively. Consistent with our previous data, the two modifications were low in the native and benign tissues and increased obviously in all types of breast cancer tissues (Fig. 4a). We scanned the slides with Leica Aperio VERSA 8 digital pathology scanner. The results indicated that both H3K27ac and H4K8ac are higher in cancer than normal tissues, highest in luminal B type (Fig. 4b). The two marks also showed very high correlation in the patient tissues (Fig. 4c), supporting our previous results.
Identification of H3K4me3 super-enhancers in breast cancer tissues
From the analyzed data, we noticed that the peak number of H3K4me3 in intergenic regions increased in tumor tissues, but not any other regions (Fig. 5a). Recent studies reported the intergenic H3K4me3 also marks enhancers [30, 31]. We speculated that the increased H3K4me3 peaks may represent a subclass of enhancers in tumor tissues and analyzed the H3K4me3-marked enhancers in our model. We defined the H3K4me3 peaks whose covered regions were more than 1 .5 kb away or whose centers were more than 3 kb away from TSS as distal H3K4me3 peaks (Fig. 5b). We identified all the distal H3K4me3 peaks and merged the peaks within 12.5 kb together, and then we ranked H3K27ac of the regions and got a plot similar to what we did for conventional super-enhancers. A tangent line with slop 1 was drawn and those higher than the intersection point were defined as H3K4me3 super-enhancers. Totally, 293 H3K4me3 super-enhancers in tumor tissues were identified (Fig. 5c and Additional file 2: Table S5). Using the same strategy, we identified 225 H3K4me3 super-enhancers in normal breast tissues (Additional file 1: Figure S5A).
The H3K4me3 super-enhancers were associated with higher transcription activity
Then, we took the groups of tumor H3K4me3 enhancers and analyzed their modifications and related gene transcription. The H3K4me3 super-enhancers showed higher H3K4me3 level in tumor than that in normal tissues, and so did H3K27ac and H4K8ac; while H3K27me3 behaved oppositely (Fig. 5d). Their adjacent genes also expressed higher in tumor than normal tissues (Fig. 5e). It is not surprising since H3K4me3 super-enhancers are identified similar to conventional super-enhancers. Interestingly, the H3K27ac signal in the H3K4me3 regions of H3k4me3 super-enhancers is much higher than the average level of conventional super-enhancers (Fig. 5f). The adjacent gene expression of tumor H3K4me3 super-enhancers was higher than tumor conventional super-enhancers (Fig. 5g). These suggest H3K4me3 super-enhancers are more active than conventional super-enhancers. EPCAM is a carcinoma-associated antigen which often highly expresses in tumor cells. We used it as a sample to show its higher expression and increased H3K4me3, H3K27ac, and H3K8ac on its enhancer (Fig. 5h). We noticed that the RNA signal at its enhancer region also increased in tumor, which may represent the upregulation of its eRNA (Fig. 5h). As a comparison, on the H3K4me3 enhancers of normal tissues, H3K4me3 did not increase significantly in tumor and has less elevation of H3K27ac (Additional file 1: Figure S5B). The related gene expression did not increase in tumor either (Additional file 1: Figure S5C). Taken together, these suggest that the increased H3K4me3 super-enhancers in tumor cells probably causes elevated transcriptional activity. Moreover, H3K4me3-marked enhancers are not limited to cancer tissues, and our analysis of online data shows that intergenic H3K4me3 peaks at the center of enhancers in IMR-90 cell lines (Additional file 1: Figure S5D).
H3K4me3 super-enhancers were associated with cancer-related genes
After we knew that tumor H3K4me3 super-enhancers are associated with increased transcription activity, we then analyzed whether their functions are associated with cancer progression. The KEGG pathway analysis showed that the adjacent genes to tumor H3K4me3 super-enhancers are not only enriched in cancer pathways, but also in some breast mammary pathways (Fig. 6a). If we divided these genes into four groups according to their expression change (Fig. 6b, c), the genes with upregulated expression in tumor (cluster 1) were associated with cancer pathways, especially breast cancer. Other genes were mostly associated with metabolic pathways and others (Fig. 6d, e). We chose some genes in cluster 1 and confirmed their expression and chromatin state with experiments (Additional file 1: Figure S6). These inform us that it is useful to combine the enhancer analysis with gene expression profiling to identify key genes in tumorigenesis and metastasis.
Inhibition of p300 repressed tumor growth in mice model
Next, we started to think whether we can repress tumorigenesis through controlling enhancer activity. Unfortunately, we could not find a chemical inhibitor for H3K4me3 on enhancer. Then, we tried to manipulate the level of H3K27ac in the cell. When investigating the molecular mechanisms for enhancer regulation in the tumor, we found the protein level of p300 increased in tumors (Fig. 7a). Since p300 is the known enzyme for H3K27ac on enhancers, and it also catalyzes acetylation on H4K8, we thought the increased p300 may be responsible for the elevation of H3K27ac and H4K8ac in tumor. We then utilized one reported inhibitor for p300, C646 , and found that the treatment of C646 to HEK293 inhibited H3K27ac, indicating the drug is functional (Fig. 7b). Then, we applied it to the MMTV-PyVT mice model (Fig. 7c). After C646 treatment, some of the tumor-like tissues were still formed. Morphologically, the tissues were flatter and had no dark blood vessels compared with the DMSO control group (Fig. 7d). The average tumor weight was less after C646 treatment (Fig. 7e), but the HE staining showed no difference of cell morphology between two groups (data not shown). The average mice weight also decreased a little bit, maybe because of the drug toxicity (Fig. 7f). These data suggest that C646 treatment inhibited some cancer features in the current condition.
P300 inhibition selectively inhibits the expression of oncogenes in breast tumors
We then performed RNA-seq and H3K27ac ChIP-seq analysis with the collected tumor tissues. The biggest tumor tissues of the three mice for each group were analyzed. The analysis of global gene expression showed that the different expressed genes (DEGs) highly expressed in DMSO group were largely enriched in cancer-related pathways, while those highly expressed in C646 group were less related (Fig. 7g, h). From the DEGs, we found that Vegfa was downregulated and its H3K27ac decreased after C646 treatment (Fig. 7i). Since Vegfa is a well-known gene to regulate angiogenesis, C646 probably inhibits tumor growth through Vegfa and other cancer-related genes.
In the current study, our proteomics and western blotting results revealed that histone H3K27ac and H4K8ac are upregulated in the tumors of MMTV-PyVT mice, which was confirmed by IHC staining of human breast cancer tissues. Our ChIP-seq analysis further discovered H4K8ac is largely co-localized with H3K27ac on chromatin, especially on distal enhancers; thus, H4K8ac may serve as another novel mark for enhancer. The enhancer profiling in the mouse tumor further found that H3K4me3 marks a group of distal enhancers and the H3K4me3 super-enhancers may become one of the important features for cancer which is coupled with higher expression of cancer-related genes. These analyses provide important proteomic and epigenomic resource for breast cancer studies. Though the intergenic regions of mouse are quite different from human, the enhancer profiling will still be useful to the future mechanistic studies in mice.
Increased activity of super-enhancers has been associated with tumorigenesis, and the super-enhancers and their target genes are considered as potential markers for tumor cell identity [5, 23]. Here, we not only identified the super-enhancers specific in the tumors of mice model, but we also identified a novel subclass of super-enhancers which are marked by H3K4me3. H3K4me3 super-enhancers are associated with higher transcription level of their adjacent genes than the conventional super-enhancers, and their H3K4me3-enriched regions are associated with higher H3K27ac and H4K8ac signals. Combined analysis of H3K4me3 super-enhancer with global gene expression identified a group of genes enriched in cancer-related pathways. The approach should be helpful to pinpoint the critical enhancers and target genes and may be useful for the future epigenome-wide association study (EWAS) in patient tumors.
A recent publication has raised the concern about the quality of H3K4me3 ChIP-seq . To ensure the quality of our data, we used three H3K4me3 antibodies from a different company and verify some enhancers identified in our study (Additional file 1: Figure S7). The results showed a very similar pattern for all three antibodies. Moreover, we downloaded the analyzed data performed with ICeChIP and good antibodies and compared the peak number, ratios, and shapes among these datasets. The results showed that our data with EMD 04-745 have a similar pattern as theirs (Additional file 1: Figure S8).
Our study reveals that the genome-wide distributions of H4K8ac and H3K27ac are largely overlapped, especially on enhancers. The histone acetylation transferases (HAT) often contain enzymatic activity to multiple histone sites; however, after analyzing the ChIP-seq data in ENCODE database, we found that the chromatin distributions of the acetylation on different sites seem to be somehow overlapped but not identical (data not shown). These raise the question whether the combination of different histone acetylation has certain biological functions? For example, selectively regulating gene transcription or contributing to genome structure? The comprehensive study of multiple histone acetylations across the genome will be required to answer it.
Besides H4K8ac and H3K27ac, we have also identified other modifications through both mass spec and western blotting, such as H3K18ac, H3K23ac, H4K12ac, H3K23me1, and H3K36me3. Unfortunately, due to lacking high-quality ChIP-grade antibodies or not enough resource, we did not pursue for their functions in tumorigenesis and development. It will be interesting to further investigate their functions and verify them in patient tissues.
We found that H4K8ac and H3K27ac are upregulated in breast cancer tissues. We also applied one inhibitor of p300, C646, to modulate the activity of enhancers in the tumor model. Though C646 did not completely inhibit tumor formation, it did significantly repress tumor formation through altering the gene expression program, especially the angiogenesis process through inhibiting Vegfa expression. Further effort to find better p300 inhibitors or the combinational use with other drugs may be promising as novel strategies for drug development.
The different histone modifications between breast cancer and normal tissues were studied. We found that H3K27ac and H4K8ac significantly in cancer and confirmed it with patient tissue chips. H4K8ac is co-localized with H3K27ac on distal enhancers. H3K4me3 marks a subgroup of super-enhancers in the intergenic regions, which are associated with higher level of H3K27ac and H4K8ac, as well as higher transcription level of their adjacent genes. One hundred sixteen H3K4me3-enriched super-enhancers with higher gene expression in tumor were identified. C646, an inhibitor of H3K27ac, repressed tumor formation through inhibiting the expression of Vegfa and other genes. Taken together, we have identified novel regulators, provide important resource to the genome-wide enhancer studies of breast cancer, and raise the possibility of cancer treatment through modulating enhancer activity.
Aim and design of the study
The aim was to study the difference of histone modifications in breast cancer tissues compared with normal tissues in the global scale. Cancer tissues and corresponding normal tissues were collected. Mass spec of histone modifications was performed and confirmed with western and patient tissue chips. Then, ChIP-seq study was performed to identify the different enhancer sites. Finally, an inhibitor of H3K27ac, which represent enhancer activity, was applied to test its effect on cancer.
Materials and reagents
Antibodies, H3K4me3 (clone MC315, Millipore 04-745), H3K27ac (Abcam Ab4729), H3K27me3 (clone C36B11, CST 9733), H4K8ac (Abcam Ab45166 for ChIP-Seq, IHC and western, Abclonal A7258 for western), H4K12ac (CST 13944), H3K27me1 (clone D3R8N, CST 84932), H3K23ac (CST 14932), H3K23me1 (Active motif, 39388), H3K9ac (clone C5B11, CST 9649), H3K9me2 (Abclonal A2359), H3K9me3 (Abcam ab176916), H3K4me1 (CST 5326), H4K20me1 (Abcam ab9051), H3K36me3 (Abcam ab9050), H4K20me3 (Abclonal A2372), H3 (Abcam Ab1791), p300 (Abcam ab14984), and β-actin (Abclonal AC026), were purchased from the indicated merchants.
Mice feeding and tissue collection
FVB/N-Tg(MMTV-PyVT)634Mul/J transgenic mice  and wild-type FVB mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (http://www.nbri-nju.com/). All mice were housed in the SPF grade room of Animal Center of College of Life Sciences, Wuhan University. All the animal operations were following the laboratory animal guidelines of Wuhan University and were approved by the Animal Experimentations Ethics Committee of Wuhan University (Protocol NO. 14110B).
Heterozygous female MMTV-PyVT (Mtv/-) mouse was backcrossed onto wild-type male FVB mouse and we selected male MMTV-PyVT (Mtv/-) mice for mating, female MMTV-PyVT (Mtv/-) and female wild-type FVB mice for subsequent experiments. Mammary tumors were gotten from female MMTV-PyVT in 12 weeks old; meanwhile, normal mammary glands from female wild-type FVB of 12 weeks old were taken out. Tumors grown in thoracic mammary gland were selected as the tumor samples, 1 mouse for 1 biological replicate. Abdominal and inguinal mammary glands were selected as the normal tissue samples, 3 mice for 1 biological replicate because of the low amount of tissue in normal mammary gland.
Tissue microarray and IHC
The tissue microarray slide was purchased from Xi’an Alenabio Co., Ltd. (Cat. NO. BR1503e and BR1505b). The BR1505b slide contained 75 cases (150 cores) of breast invasive ductal carcinoma samples. The BR1503e slide contained 3 cases (6 cores) of adjacent normal breast tissue, 3 cases (6 cores) of breast fibroadenoma samples, 2 cases (4 cores) of breast cystosarcoma phyllodes samples, 7 cases (14 cores) of breast intraductal carcinoma samples, and 60 cases (120 cores) of breast invasive ductal carcinoma samples.
The slides were deparaffinized, rehydrated, and subjected to heat-mediated antigen retrieval. For immunohistochemistry (IHC) analysis, the sections were incubated with 3% H2O2 for 15 min at room temperature to quench endogenous peroxidase activity. After incubating in normal goat serum for 1 h, sections were treated with primary antibody at 4 °C overnight. IHC analysis of tumor samples was performed using primary antibodies against H4K8ac (dilution 1:200; Abcam ab45166) and H3K27ac (dilution 1:200; Abcam ab4729). The sections were then washed three times in PBS and treated for 30 min with biotinylated goat-anti-rabbit IgG secondary antibodies. After washing three times in PBS, sections were incubated with streptavidin-conjugated HRP. After washing three times in PBS for 5 min each, specific detection was developed with 303-diaminobenzidine (DAB-2031). Images were taken by Leica Aperio VERSA 8 digital pathology scanner.
For information about other experimental methods, please refer to the supplemental materials.
Molecular subtypes of breast cancer
Molecular subtypes of breast cancer were determined as follows: Luminal A—breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive), HER-2 negative, and has low levels of the protein Ki-67. Luminal B—breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive) and either HER-2 positive or HER-2 negative with high levels of Ki-67. HER-2-type breast cancer is hormone-receptor negative (estrogen-receptor and progesterone-receptor negative) and HER-2 positive. Basal-like breast cancer is hormone-receptor negative (estrogen-receptor and progesterone-receptor negative) and HER-2 negative.
IHC image analysis
The digital slides were taken by Leica Aperio VERSA 8 digital pathology scanner and then analyzed by Aperio colocalization image analysis algorithm. First, we use ImageScope to view the digital slides and select the appropriate area to calibrate the color and threshold of hematoxylin and DAB. Then, we create an algorithm macro and register it on the eSlide Manager. The eSlide Manager provides a convenient tool for batch analysis of slides. We used the selected algorithm macro to analyze the digital slides. The percent of DAB represented the protein concentration.
Histone extraction for LC-MS/MS analysis
Mouse breast tissues were minced and homogenized on ice in 1:10 (wt/v) NIB buffer within 10 mM sodium butyrate, 1 × protease inhibitor cocktail, 1 × phosphatase inhibitor cocktail, and 0.2% NP-40. After homogenization for 10 min, the nuclei were pelleted by centrifugation for 5 min at 1000g. The nuclei samples were washed gently three times in 1:10 (v/v) NIB buffer without 0.2% NP-40. Histones were then extracted from the nuclei in 1:5 (v/v) 0.2 M H2SO4 for 3 h and precipitated by 33% TCA on ice overnight. Histones were washed using ice-cold acetone supplemented with 0.1% HCl and then ice-cold acetone without 0.1% HCl, respectively. Histones were dried in a vacuum centrifuge. The concentration of extracted histone was measured by the bio-rad protein assay. The purity and quality of histones were affirmed by 15% SDS-PAGE analysis and Coomassie staining.
Proteomics studies of histone modifications
The buffer was prepared with the following: HPLC-grade acetonitrile (ACN) (Millipore), propionic anhydride (Sigma), sequencing-grade modified trypsin (Promega), HPLC buffer A:0.1% formic acid (Sigma), and HPLC buffer B: 0.1% formic acid in ACN.
Chemical derivatization and digestion of histones
Twenty micrograms of histone proteins were redissolved in 30 μl 50 mM NH4HCO3. The lysine residues and N-terminus of histone were chemically derivatizated twice by propionic anhydride with 1:3 (v/v) acetonitrile at 37 °C and completely dried. Histone proteins were then re-suspended in 30 μl 50 mM NH4HCO3 and digested by 1:10 (wt/wt) trypsin at 37 °C overnight. Subsequently, the histone peptides were derivatizated twice with propionic anhydride to label the peptide N-terminus generated from the trypsin digestion and dried completely via a vacuum centrifuge.
Stage tip desalting
Stage tips were prepared in the house using double-layered reversed-phase material C18 in 200 μl of tip. Stage tips were washed using 70% ACN/0.1% TFA and balanced using 0.1% TFA. Histone peptides were redissolved in 0.1% TFA and loaded in stage tips twice. The stage tips within histone peptides were washed twice by 0.1% TFA for removing extra salt. Histone peptides were eluted from stage tips using 50% ACN/0.1% TFA and 70% ACN/0.1% TFA and dried in a vacuum centrifuge.
LC-MS/MS of histone peptides
Histone peptides were resuspended with HPLC buffer A. Peptides were loaded on to 100 μm i.d. × 2-cm Reprosil-Pur C18-AQ (5 μm; Thermo Scientific, CA) trap column and separated by 75 μm i.d. × 25-cm Reprosil-Pur C18-AQ (2 μm; Thermo Scientific, CA) analytical column. The HPLC gradient was as follows: from 5 to 35% buffer B in 50 min, from 35 to 95% buffer B for 5 min, and 95% buffer B for 5 min at a flow rate of 250 nL/min. NanoLC was coupled to a Q Exactive HF mass spectrometer (Thermo Scientific). For data-independent acquisition (DIA), two full-scan MS spectra (m/z 300–1100) at a resolution of 60,000 were acquired in the orbitrap within a DIA duty cycle, and 16 MS/MS were performed at a resolution of 60,000 with an isolation window of 50 Da. Normalized collision energy (NCE) was set to 27.
The raw DIA MS data were processed using Epiprofile, which allowed quantitative analysis of histone peptides with multiple PTMs. Based on previous knowledge of histone peptide masses and elution profiles, the retention times and peak areas of histone peptides were extracted under the curve in mass spectra. A histone peptide with multiple PTMs was quantified in relative abundance, which was the percentage of the area of this histone peptide with particular PTM in summed total area of the histone peptide in all forms. The relative abundance of a single histone mark was obtained by summing the relative abundances in all the modified peptide forms. All quantitative results were expressed as the mean ± SD (standard deviation). For normal and tumor comparison, data were analyzed by homoscedastic t test based on biological replicates. Differences were considered statistically significant when the p values were less than 0.05.
Epigenomic studies of histone modifications of mouse tissues
Chromatin immunoprecipitation (ChIP) assay of mouse tissues
Sixty milligrams of each tissue was cut into 1-mm3 pieces in PBS with protease inhibitor. Tissue pieces were cross-linked for 10 min at room temperature with 1% formaldehyde and then quenched with 0.125 M of glycine for 5 min. Cross-linked tissues were triturated by trituration equipment for 30 s and then centrifuged at 12000 rpm, 4 °C for 5 min. Supernatant with massive oil was discarded and the precipitates were lysed with 1 mL lysis buffer (50 mM Tris-HCl pH 8.0, 0.1% SDS, 5 mM EDTA) and incubated for 5 min with gentle rotation. After centrifugation at 12000 rpm, 4 °C for 2 min, lysates were washed once by digestion buffer (50 mM Tris-HCl pH 8.0, 1 mM CaCl2, 0.2% Triton X-100). Washed lysates were incubated in 630-μL digestion buffer with 1-μL MNase (NEB, M0247S) at 37 °C for 20 min and then quenched with 8 μL 0.5 M EDTA. Whole lysates were sonicated and the supernatants were taken out after centrifugation. Thirty microliters of supernatants were taken for checking the efficiency of MNase digestion. Immunoprecipitation was further performed with 150-μL sheared chromatin, 2-μg antibody, 50-μL Protein G sepharose beads and 800-μL dilution buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS) overnight at 4 °C. Next day, immuno-complexes were washed once with Wash buffer I (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), once with Wash buffer II (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), once with Wash buffer III (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% Na-deoxycholate, 1% NP-40), and twice with TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). The immune complexes were eluted twice with 100-μL elution buffer (1% SDS, 0 .1M NaHCO3, 20 mg/mL Proteinase K) at room temperature. The elution was incubated at 65 °C for 6 h and then purified with DNA purification kit (TIANGEN DP214-03).
ChIP-seq library construction
ChIP-seq libraries were constructed by VATHS Universal DNA Library Prep Kit for Illumina (Vazyme ND604). Briefly, 50 μL of purified ChIP DNA (8–10 ng) was end-repaired for dA tailing, followed by adaptor ligation. Each adaptor was marked with a barcode of 6 bp which can be recognized after mixing different samples together. Adaptor-ligated ChIP DNA was purified by AMPure XP beads (1:1) and then amplified by PCR of 11–13 cycles with the primer matching with adaptor universal part. Amplified ChIP DNA was purified again using AMPure XP beads (1:1) in 35-μL EB elution buffer. For multiplexing, libraries with different barcode were mixed together with equal molar quantities by considering appropriate sequencing depth (30–40 million reads per library). Libraries were sequenced by Illumina Hi-seq X Ten platform with pair-end reads of 150 bp.
RNA-seq library construction
For both normal mammary gland and tumor samples, a 20-mg tissue was used for RNA extraction. Total RNA was extracted by using EASYspin RNA Mini Kit (Aidlab RN07). Briefly, tissue was triturated by trituration equipment for 20 s in lysis buffer provided by kit and then centrifuged at 12000 rpm, 4 °C for 5 min. Liquid between precipitates on the bottom and oil on the top was taken out and pipetted 10 times using 1 mL syringe. The entire volume of liquid was added into adsorption column provided by kit and RNA would retain in column while other components include DNA and protein would be washed out by several buffers. Total RNA eluted in 50-μL RNase-free water. RNA-seq libraries were constructed by NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB E7490) and NEBNext Ultra II Non-Directional RNA Second Strand Synthesis Module (NEB E6111). Briefly, mRNA was extracted by poly-A selected with magnetic beads with poly-T and transformed into cDNA by first and second strand synthesis. Newly synthesized cDNA was purified by AMPure XP beads (1:1) and eluted in 50-μL nucleotide-free water. Subsequent procedures were the same as ChIP-seq library construction described previously except the sequencing depth of 20 million reads per library. RNA-seq libraries were sequenced by Illumina Hi-seq X Ten platform with pair-end reads of 150 bp.
ChIP-seq data processing
All ChIP-seq raw fastq data were cleaned by removing the adaptor sequence. Cutadapt (version 1.16, http://cutadapt.readthedocs.io/en/stable/guide.html ) was used for this step with the parameters -u 10 -u -15 -U 10 -U -15 -m 30. Cleaned reads were aligned to the mouse reference genome (mm10) using BWA (version 0.7.15, http://bio-bwa.sourceforge.net ) with the default settings. Peaks calling was finished by MACS2 (version 2.1.1, https://github.com/taoliu/MACS ) with the parameters --nomodel --keep-dup all -p 1E-10 --broad --broad-cutoff 1E-10 --extsize 147. Replicates of ChIP-seq data were pooled for downstream analysis.
RNA-seq data processing
All RNA-seq raw fastq data were removed of adaptor sequence as the same way of ChIP-seq data processing. Cleaned reads were mapped to the mouse reference genome (mm10) using TopHat (version 2.1.1, http://ccb.jhu.edu/software/tophat/index.shtml ) with the default settings. The gene expression level was calculated by Cufflinks (version 2.2.1, http://cole-trapnell-lab.github.io/cufflinks ) and normalized by fragments per kilobase of bin per million mapped reads (FPKM).
Comparison between different histone markers and between replicates
For the comparison in genome-wide, the entire genome was divided into massive 2 kb windows and the enrichment of modification in each bin would be considered to calculate correlation. For the comparison in enhancers, signal of modification in each enhancer was normalized by reads of bin per million mapped reads (RPM) and such enrichment was used for calculating correlation.
Identification of typical and super-enhancers
Enhancers were identified by the algorithm developed by Richard A. Young, 2013. Briefly, significant distal H3K27ac peaks (peak boundary 1.5 kb or peak center 3 kb away from gene TSS) were identified, and the peaks whose distance was shorter than 12.5 kb were merged together as distal enhancers. The distal enhancers were ranked by the total signal of H3K27ac, and a plot was drawn to show the increased H3K27ac signal. Then, a tangent line with slope 1 was found of the curve and the intersection point was determined as the infection point. Enhancers above this point were defined as super-enhancers; meanwhile, enhancers below this point were defined as typical enhancers.
Identification of H3K4me3-enriched typical and super-enhancers
Firstly, we identified significant distal H3K4me3 peaks using the same way of defining significant distal H3K27ac peaks described previously, and nearby peaks of a distance shorter than 12.5 kb were merged together. Similar to the strategy to identify super-enhancers, H3K27ac in the regions were ranked and a plot was drawn. A tangent line with slop 1 was drawn and the intersection point was found. The enhancers above the intersection point were defined as H3K4me3 super-enhancer.
Morgan MA, Shilatifard A. Chromatin signatures of cancer. Genes Dev. 2015;29(3):238–49.
Brookes E, Shi Y. Diverse epigenetic mechanisms of human disease. Annu Rev Genet. 2014;48:237–68.
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.
Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8(6):1409–20.
Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–34.
Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463(7279):360–3.
Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153(3):590–600.
Zhu K, Lei PJ, Ju LG, Wang X, Huang K, Yang B, et al. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing. Nucleic Acids Res. 2017;45(1):92–105.
Hu D, Shilatifard A. Epigenetics of hematopoiesis and hematological malignancies. Genes Dev. 2016;30(18):2021–41.
Zhao QY, Lei PJ, Zhang X, Zheng JY, Wang HY, Zhao J, et al. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. Clin Epigenetics. 2016;8:34.
Mishra S, Van Rechem C, Pal S, Clarke TL, Chakraborty D, Mahan SD, et al. Cross-talk between lysine-modifying enzymes controls site-specific DNA amplifications. Cell. 2018;174(4):803–817.e16.
Metzger E, Stepputtis SS, Strietz J, Preca BT, Urban S, Willmann D, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017;77(21):5900–12.
Murakawa Y, Yoshihara M, Kawaji H, Nishikawa M, Zayed H, Suzuki H, et al. Enhanced identification of transcriptional enhancers provides mechanistic insights into diseases. Trends Genet. 2016;32(2):76–88.
Medina-Rivera A, Santiago-Algarra D, Puthier D, Spicuglia S. Widespread enhancer activity from core promoters. Trends Biochem Sci. 2018;43(6):452–68.
Spurrell CH, Dickel DE, Visel A. The ties that bind: mapping the dynamic enhancer-promoter interactome. Cell. 2016;167(5):1163–6.
Rickels R, Herz HM, Sze CC, Cao K, Morgan MA, Collings CK, et al. Histone H3K4 monomethylation catalyzed by Trr and mammalian COMPASS-like proteins at enhancers is dispensable for development and viability. Nat Genet. 2017;49(11):1647–53.
Hu D, Gao X, Morgan MA, Herz HM, Smith ER, Shilatifard A. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol. 2013;33(23):4745–54.
Rickels R, Shilatifard A. Enhancer logic and mechanics in development and disease. Trends Cell Biol. 2018;28(8):608–30.
Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825–37.
Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, et al. Enhancer reprogramming promotes pancreatic cancer metastasis. Cell. 2017;170(5):875–88 e20.
Villar D, Berthelot C, Aldridge S, Rayner TF, Lukk M, Pignatelli M, et al. Enhancer evolution across 20 mammalian species. Cell. 2015;160(3):554–66.
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307–19.
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–47.
Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol Cell. 2015;58(6):1028–39.
Yuan ZF, Sidoli S, Marchione DM, Simithy J, Janssen KA, Szurgot MR, et al. EpiProfile 2.0: a computational platform for processing epi-proteomics mass spectrometry data. J Proteome Res. 2018;17(7):2533–41.
Yuan ZF, Lin S, Molden RC, Cao XJ, Bhanu NV, Wang X, et al. EpiProfile quantifies histone peptides with modifications by extracting retention time and intensity in high-resolution mass spectra. Mol Cell Proteomics. 2015;14(6):1696–707.
Sidoli S, Bhanu NV, Karch KR, Wang X, Garcia BA. Complete workflow for analysis of histone post-translational modifications using bottom-up mass spectrometry: from histone extraction to data analysis. J Vis Exp. 2016;(111):54112.
Lin S, Wein S, Gonzales-Cope M, Otte GL, Yuan ZF, Afjehi-Sadat L, et al. Stable-isotope-labeled histone peptide library for histone post-translational modification and variant quantification by mass spectrometry. Mol Cell Proteomics. 2014;13(9):2450–66.
Guo Q, Sidoli S, Garcia BA, Zhao X. Assessment of quantification precision of histone post-translational modifications by using an ion trap and down to 50000 cells as starting material. J Proteome Res. 2018;17(1):234–42.
Hu D, Gao X, Cao K, Morgan MA, Mas G, Smith ER, et al. Not all H3K4 methylations are created equal: Mll2/COMPASS dependency in primordial germ cell specification. Mol Cell. 2017;65(3):460–75 e6.
Shen H, Xu W, Guo R, Rong B, Gu L, Wang Z, et al. Suppression of enhancer overactivation by a RACK7-histone demethylase complex. Cell. 2016;165(2):331–42.
Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010;17(5):471–82.
Shah RN, Grzybowski AT, Cornett EM, Johnstone AL, Dickson BM, Boone BA, et al. Examining the roles of H3K4 methylation states with systematically characterized antibodies. Mol Cell. 2018;72(1):162–77 e7.
Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954–61.
We thank all the grant providers, and other people who gave suggestions.
This work was supported by the Ministry of Science and Technology of China (2016YFA0502100), National Natural Science Foundation of China to Min Wu (31470771, 31521091 and 31771503), Lian-Yun Li (31670874) and Xiao-Lu Zhao (31870827), Science and Technology Department of Hubei Province of China (CXZD2017000188), Hubei Natural Science Foundation (2018CFB603).
Availability of data and materials
The original deep sequencing data were submitted to the GEO database, Acc. NO. GSE118812.
Ethics approval and consent to participate
All the animal operations were following the laboratory animal guidelines of Wuhan University and were approved by the Animal Experimentations Ethics Committee of Wuhan University (Protocol NO. 14110B). No patient study was involved and the consent to participate is not applicable.
Consent for publication
All the authors have read the manuscript and agreed to publish the manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure S1. Multiple modifications on two peptides of histone H3 and H4. Figure S2. The proteomic pattern of histone modifications in breast cancer model. Figure S3. Correlation of H3K27ac and H4K8ac distribution on chromatin. Figure S4. Enhancer analysis of normal tissues. Figure S5. H3K4me3 super enhancer in normal tissues. Figure S6. UCSC browser view showing the histone modification on selected genes. Figure S7. ChIP-PCR verification for H3K4me3 ChIP-Seqresults. Figure S8. Quality analysis of H3K4me3 ChIP-Seqdata with EMD 04-745. (PDF 29519 kb)
Table S1. List of the relative abundance of all histone peptides. Table S2. List of the relative abundance of histone H3 and H4 peptides. Table S3. List of the relative abundance of single PTMs on histone H3 and H4. Table S4. Identified super-enhancers in tumor. Table S5. Identified H3K4me3 enriched super enhancers in tumor. (XLSX 189 kb)
About this article
Cite this article
Li, QL., Wang, DY., Ju, LG. et al. The hyper-activation of transcriptional enhancers in breast cancer. Clin Epigenet 11, 48 (2019). https://doi.org/10.1186/s13148-019-0645-x
- Breast cancer